Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Saphris Approved for Two New Uses

By Drug Discovery Trends Editor | September 8, 2010

TRENTON, N.J. (AP) – Merck & Co. said its schizophrenia drug Saphris has been approved for two additional uses by the Food and Drug Administration.

The drug was first approved in August 2009 for treating acute schizophrenia episodes in adults and acute mania or manic-depressive behavior in adults with bipolar disorder.

Merck says the FDA now has approved Saphris for ongoing treatment of schizophrenia and for treating acute mania or manic-depressive behavior in adult bipolar patients along with lithium, a mood-stabilizing drug often used to treat mania, or the antiseizure drug valproate.

Saphris carries the FDA’s strongest caution, a black box warning, that it nearly doubles risk of death in elderly patients with dementia.

Like similar drugs, it has many other serious potential risks, including strokes, heart problems, high blood sugar and diabetes, suicide, seizures, fainting, a drop in infection-fighting white blood cells, sedation and impaired thinking, and neuroleptic malignant syndrome, a life-threatening neurological disorder.

Merck has not yet reported sales figures for Saphris, also known as asenapine. That indicates the drug’s quarterly sales have not yet topped Merck’s threshold for reporting individual product sales, $200 million a year or $50 million in a quarter.

Saphris, just launched in the fourth quarter, has lots of tough competition in the lucrative market for antipsychotic medicines, which are approved for treating schizophrenia and bipolar disorder. Rival drugs include Johnson & Johnson’s Risperdal, Eli Lilly & Co.’s Zyprexa, AstraZeneca PLC’s Seroquel, Pfizer Inc.’s Geodon and Bristol-Myers Squibb Co.’s Abilify.

The drugs are widely prescribed for unapproved uses, including other psychiatric conditions and insomnia, significantly boosting their sales.

Last year, antipsychotic drugs brought in $23.25 billion in worldwide sales, according to drug data firm IMS Health.

Saphris was developed by Schering-Plough Corp., which Merck bought last November.

Date: September 7, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50